What is CTI BioPharma Corp. (CTIC)?

CTI BioPharma Corp. (CTIC) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of CTIC?

The current price of CTIC is $9.10. Prices are updated in real time on Stocks360.

What is CTIC's price-to-earnings (PE) ratio?

CTIC's trailing twelve-month PE ratio is -11.51, based on current price and earnings per share data available on Stocks360.

What is CTIC's market capitalization?

CTIC's market capitalization is $1,199,448,600.00, placing it in the small-cap tier.

CTI BioPharma Corp. (CTIC)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$9.10

Market Cap

$1.20B

PE (TTM)

-11.51

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

0.83

Day Range

$9.09 – $9.10

52-wk Range

$4.01 – $9.10

Avg Volume

N/A

Volume

5.56M

CTI BioPharma Corp. (CTIC) is a publicly traded company in the Healthcare sector. Latest price: $9.10. Market cap $1.20B. Trailing PE -11.51. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Earnings

Most Recent

Aug 14, 2023

EPS $-0.21 vs est. $-0.08

Missed by $0.13

Proprietary Signals

Signal snapshot temporarily unavailable.

About CTI BioPharma Corp.

CTI BioPharma Corp. is a biopharmaceutical company dedicated to the discovery, advancement, and commercialization of innovative, targeted treatments for blood cancers within the United States. Its key product is VONJO (pacritinib), an oral kinase inhibitor currently under investigation, specifically designed to target JAK2, FLT3, IRAK1, and CSF1R for the management of adult patients with myelofibrosis. The company holds licensing and collaboration agreements with Teva Pharmaceutical Industries Ltd., SBIO Pte Ltd., and Baxalta. Established in 1991 and based in Seattle, Washington, CTI BioPharma Corp. was previously known as Cell Therapeutics, Inc., adopting its current name in May 2014.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-11.51×
P/S (TTM)	22.23×
P/B	-59.35×
P/FCF (TTM)	-11.29×
EV / EBITDA	-15.65×
EV / Sales	22.60×
Earnings Yield	-8.73%
Free Cash Flow Yield	-8.85%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$1.22B
Revenue (TTM)	$53.95M
Net Income (TTM)	-$104.68M
Free Cash Flow (TTM)	-$93.33M
Net Debt	$19.54M
Working Capital	$18.26M
Gross Margin	93.49%
Operating Margin	-147.91%
Net Margin	-168.76%
Return on Equity	1318.48%
Return on Invested Capital	-84.24%